I graduated from the Medical University in Sofia, Bulgaria, in 1984 as the valedictorian of my class and received the Golden Hippocrates Statue and Medal. I initially worked as an Assistant Professor in the Department of Endocrinology at the same university, focusing on Internal Medicine and Endocrinology. In 1994, I moved to the USA and completed an Internal Medicine Residency at Lincoln Medical and Mental Health Center in the Bronx, New York. I then served as an Attending Physician and Chair of Medicine from 1997 to 2020 at John Peter Smith Hospital in Fort Worth, Texas. I taught hundreds of internal medicine residents, family practice residents, and medical students from both the hospital and the University of North Texas Health Science Center in Fort Worth. In 2020, I relocated to Las Vegas, Nevada. I am currently the Transitional Year Residency Program Director and a core faculty member of the Internal Medicine Residency Program at Mountain View Hospital in Las Vegas, as well as a member of the Sunrise Health GME Consortium.  I am a board-certified endocrinologist and internist by the ABIM in the USA and the European Union. I have published 114  peer-reviewed articles on the pathogenesis and treatment of type 1 and type 2 diabetes, thyroid disorders, and male hypogonadism in the USA, France, England, India, and Bulgaria. My Continuous Glucose Monitoring Project received first place in the Quality category at the Far West Research Division Symposium in Las Vegas, Nevada, in 2021, 2022, 2023, and 2024.  I have led three international multicenter scientific trials and authored six chapters on endocrinology in books published in England in 2021 and 2023. I am the Principal Investigator on a trial about the introduction of Continuous Glucose monitoring in an internal medicine Residency clinic, which is the first such trial in the USA. I delivered hundreds of lectures at various local, national, and international meetings on DM type 2, HTN, DVT, and related topics. I participated in 10 international scientific conferences on Diabetes, Technologies in Diabetes, and Primary Care in England, Austria, and Switzerland, delivering Webex presentations as a specially invited speaker. I worked in England with the renowned immuno-endocrinologist Prof. Franco Bottazzo, who discovered the Autoimmune nature of type 1 Diabetes Mellitus in 1974, from 1991 to 1992. In 1991, in his laboratory in London, England, I first observed increased expression of the adhesion molecule CD44 in snap-frozen sections and cell cultures from various autoimmune thyroid diseases.  I am interested in a Program Director of Internal Medicine position with extensive teaching and clinical experience. I have served as an Associate and Full Professor for 28 years as an academic faculty member at hospitals and universities in Fort Worth, Texas; Dallas, Texas; and Las Vegas, Nevada. I served as Course Director in Endocrinology for second-year Medical Students at the University of North Texas Health Science Center (UNTHSC) in Fort Worth, TX, from 2017 to 2018, holding the rank of Professor.  I have been a Professor in the Department of Medicine at the TCU and UNTHSC School of Medicine in Fort Worth, TX, since 2017. I am also an Adjunct Clinical Professor in the Department of Medicine at Touro Osteopathic Medical School in Henderson, Nevada, and a Full Professor of Medicine at the University of Las Vegas, Nevada.  I was elected a Fellow of the American College of Physicians and recognized as a Top Doctor Internist for 2018 in Fort Worth, TX. Additionally, I was named Top Endocrinologist and Internist in Las Vegas, Nevada, in 2021, 2022, 2023, 2024, and 2025.    

CGM Monitoring in Internal Medicine Residency Clinic: Prospective Trial - 4 Months of Data  A. Manov, K. Mefferd, J. Everett, J. Chen, DO, Y. Nam, B. Krason, P. Chaganlal, E. Tupas, T. Rushton, T. Rogers, J. Matthew, A. Panta  Internal Medicine and Transitional Year Residency Program, Mountain View Hospital, Las Vegas, Nevada Sunrise Health GME Consortium, Las Vegas, Nevada  Corresponding Author: Andre Manov, MD  Key Words: Continuous Glucose Monitoring (CGM), GMI, HbA1c, Diabetes Mellitus Type 2, Internal Medicine Residency Clinic, Board-Certified Endocrinologist, Blood Glucose  Acknowledgment: We wish to thank the Research Department, Sunrise Health GME Consortium, Mountain View Hospital, Las Vegas, Nevada.  Disclaimer: This research was supported in whole or in part by HCA Healthcare and/or an organization affiliated with HCA Healthcare. The views expressed are solely those of the authors and do not necessarily represent the official positions of HCA Healthcare or any related entities.   This study’s information is based on results from patients using Dexcom G6, G7, or Freestyle Libre continuous glucose monitoring (CGM) devices, primarily Dexcom G6 or G7. Our study does not evaluate the effectiveness of other similar CGM devices and does not endorse any specific brand. More research is needed to fully understand the use and effectiveness of CGM devices. The findings of this evaluation should not be used to make medical decisions and should always be considered alongside professional medical advice.  Funding Source: No disclosed sources for any of the authors.  Conflicts of Interest: None to be disclosed for any of the authors.